User Image Cart Icon 0 Search Image
  • Home > Blog > Inhibition Of Renal Glucose Reabsorption

Inhibition Of Renal Glucose Reabsorption

  1. Inhibition of Renal Glucose Reabsorption: a novel strategy for achieving Glucose control in type 2 diabetes mellitus
  2. Inhibition of Renal Glucose Reabsorption as a novel treatment for diabetes patients
  3. Renal Glucose Reabsorption inhibitors to treat diabetes
  4. Characterization of Renal Glucose Reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
  5. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in Renal Glucose Reabsorption in humans
  6. Development of the Renal Glucose Reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2
  7. Effect of Lepidium sativum L. on Renal Glucose Reabsorption and urinary TGF‐β1 levels in diabetic rats
  8. Selective SGLT2 Inhibition by tofogliflozin reduces Renal Glucose Reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
  9. Antihyperglycemic effect of T-1095 via Inhibition of Renal Na+-Glucose cotransporters in streptozotocin-induced diabetic rats
  10. Renal Glucose transporters: novel targets for hyperglycemia management
  11. Role of the kidney in normal Glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
  12. Renal, metabolic and cardiovascular considerations of SGLT2 Inhibition
  13. Sodium-Glucose cotransporter-2 Inhibition and the glomerulus: a review
  14. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
  15. Type 2 sodium-Glucose cotransporter (SGLT2) inhibitors: from familial Renal glucosuria to the treatment of type 2 diabetes mellitus
  16. Inhibition of the intestinal sodium‐coupled Glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood Glucose levels in mice …
  17. Glucose metabolism in the kidney: neurohormonal activation and heart failure development
  18. The role of the kidney and sodium-Glucose cotransporter-2 Inhibition in diabetes management
  19. Effect of phlorhizin on Renal Glucose and phosphate transport in the dog
  20. Exploring newer target sodium Glucose transporter 2 for the treatment of diabetes mellitus
  21. Glucose control by the kidney: an emerging target in diabetes
  22. Targeting Renal Glucose Reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
  23. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
  24. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors
  25. Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes
  26. Dapagliflozin: a sodium Glucose cotransporter 2 inhibitor in development for type 2 diabetes
  27. SGLT2 Inhibition in diabetes mellitus: rationale and clinical prospects
  28. Effect of sodium-Glucose cotransport Inhibition on polycystic kidney disease progression in PCK rats
  29. Sodium Glucose co-transporter 2 (SGLT2) inhibitor
  30. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary Glucose excretion in healthy subjects
  31. The role of the kidneys in Glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium Glucose co-transporter 2 …
  32. SGLT2 Inhibition—a novel strategy for diabetes treatment
  33. Tofogliflozin, a potent and highly specific sodium/Glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
  34. SGLT2 inhibitors: molecular design and potential differences in effect
  35. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice
  36. Sodium‐Glucose co‐transporter (SGLT) and Glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
  37. Does urea Reabsorption occur via the Glucose pathway in the kidney of the freshwater rainbow trout?
  38. Model analysis of effect of canagliflozin (Invokana), a sodium–Glucose cotransporter 2 inhibitor, to alter plasma 1, 5-anhydroglucitol
  39. Modified cycloartanes with improved inhibitory effect on SGLT-mediated Glucose uptake in human Renal proximal tubular cells
  40. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
  41. Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats
  42. Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
  43. Hypoglycaemic activity of Retama raetam in rats
  44. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-Glucose co-transporter type 2
  45. Role of the kidney in Glucose homeostasis: implications for SGLT-2 Inhibition in the treatment of type 2 diabetes mellitus
  46. Sodium-Glucose co-transport inhibitors
  47. Dapagliflozin: a selective sodium-Glucose co-transporter-2 inhibitor in type 2 diabetes.
  48. In vitro–in vivo correlation of the Inhibition potency of sodium-Glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach
  49. Siphoning Blood Glucose: A Novel Therapy
  50. T-1095, a Renal Na+-Glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
  51. The role of the kidneys in Glucose homeostasis: a new path towards normalizing glycaemia
  52. Dapagliflozin, a selective SGLT2 inhibitor, improves Glucose homeostasis in normal and diabetic rats
  53. Sodium Glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes
  54. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent Glucose co-transporter 2, in …
  55. Targeting the kidney and Glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 Inhibition as a new option for treatment of type 2 …
  56. Lowering plasma Glucose concentration by inhibiting Renal sodium–Glucose cotransport
  57. Development of the sodium-Glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus
  58. Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent Glucose transporter 2 inhibitor …
  59. Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected Renal effects
  60. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta‐analysis
  61. Associations of insulin levels and insulin resistance with urine Glucose excretion independent of blood Glucose in Chinese adults with prediabetes and newly …
  62. Unmasking and aggravation of polycythemia vera by canagliflozin
  63. Effects of Kaempferia parviflora Extract on Glucose Transporters in Human Renal Proximal Tubular Cells
  64. Renal sodium-Glucose cotransporter Inhibition in the management of type 2 diabetes mellitus
  65. Meet the SGLT2 inhibitors: these new type 2 diabetes medications block Glucose Reabsorption by the kidneys
  66. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
  67. Sodium-Glucose co-transporters and their Inhibition: clinical physiology
  68. The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-Glucose co-transporter 2 (SGLT-2)
  69. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
  70. SODIUM-Glucose TRANSPORTER 2 Inhibition–A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
  71. SGLT2 inhibitors for type 2 diabetes
  72. Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases
  73. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
  74. Antidiabetic drugs and the kidney
  75. Differentiating sodium-Glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
  76. Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model
  77. Tofogliflozin: the road goes ever on
  78. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
  79. Distribution of Glucose transporters in Renal diseases
  80. New potent antihyperglycemic agents in db/db mice: Synthesis and structure− activity relationship studies of (4-substituted benzyl)(trifluoromethyl) pyrazoles and …
  81. The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
  82. Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
  83. Dapagliflozin attenuates Renal gluconeogenic enzyme expression in obese rats
  84. Sodium–Glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
  85. A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy …
  86. Sodium Glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
  87. A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
  88. Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, for the management of type 2 diabetes
  89. Empagliflozin, a sodium Glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
  90. Mechanistic evaluation of the effect of sodium‐dependent Glucose transporter 2 inhibitors on delayed Glucose absorption in patients with type 2 diabetes mellitus …
  91. The Role of the Kidney in Glucose Homeostasis
  92. Natural products as lead compounds for sodium Glucose cotransporter (SGLT) inhibitors
  93. Role of sodium-Glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
  94. The Kidneys in Type 2 Diabetes Disturbed Glucose Homeostasis to Mechanism-Based Therapy
  95. Sodium-Glucose cotransporter 2 Inhibition in type 1 diabetes: simultaneous Glucose lowering and Renal protection?
  96. Kidney in diabetes: from organ damage target to therapeutic target
  97. The Renal effects of SGLT2 inhibitors and a mini-review of the literature
  98. Preventive effects of flavonoids on alloxan-induced diabetes mellitus in rats
  99. Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
  100. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–Glucose co‐transporter type 2, in Japanese subjects without and with …
  101. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐Glucose co‐transporter‐2, in people with type 2 diabetes mellitus
  102. Potent sodium/Glucose cotransporter SGLT1/2 dual Inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in …
  103. DAPA-HF trial: dapagliflozin evolves from a Glucose-lowering agent to a therapy for heart failure
  104. Dapagliflozin: A new drug for treatment of type 2 diabetes mellitus
  105. Dapagliflozin for the treatment of type 2 diabetes
  106. Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐Glucose cotransporter inhibitor T‐1095
  107. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
  108. Sodium-Glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?
  109. p63 and SOX2 dictate Glucose reliance and metabolic vulnerabilities in squamous cell carcinomas
  110. Role of sodium/Glucose cotransporter Inhibition on a rat model of angiotensin II–dependent kidney damage
  111. Dapagliflozin: a review on efficacy, clinical effectiveness and safety
  112. Increased waist-to-hip ratio is associated with decreased urine Glucose excretion in adults with no history of diabetes
  113. EMPA-REG OUTCOME: the nephrologist’s point of view
  114. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
  115. Effect of Renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes …
  116. Structure-activity relationships of preventive effects of flavonoids in alloxan-induced diabetes mellitus in rats
  117. Acute diuretic effect of aqueous extract of Retama raetam in normal rats
  118. Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
  119. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent Glucose cotransporter 2 and clinical candidate for the …
  120. Impact of sodium–Glucose cotransporter 2 inhibitors on blood pressure
  121. Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes
  122. Effect of sodium‐Glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
  123. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
  124. SGLT2 inhibitors in patients with type 2 diabetes and Renal disease: overview of current evidence
  125. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
  126. Sodium-Glucose Transporter 2 Inhibitors and Kidney
  127. Use of Sodium–Glucose Cotransporter 2 (SGLT-2) Inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
  128. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes
  129. Pharmacogenetics of novel Glucose-lowering drugs
  130. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate Renal impairment
  131. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
  132. Short commentary on empagliflozin and its potential clinical impact
  133. Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats
  134. The novel role of the kidney in diabetes management: Sodium-Glucose Co-Transporter 2 Inhibitors
  135. Study of the hypoglycaemic activity of Lepidium sativum L. aqueous extract in normal and diabetic rats
  136. Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-Glucose transporters (SGLTs) in mice
  137. Long-term study of patients with type 2 diabetes and moderate Renal impairment shows that dapagliflozin reduces weight and blood pressure but does not …
  138. Evolution of sodium Glucose co-transporter 2 inhibitors as anti-diabetic agents
  139. Use of a sodium–Glucose cotransporter 2 inhibitor in a patient with chronic kidney disease
  140. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’
  141. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
  142. Identification of phlorizin binding domains in sodium-Glucose cotransporter family: SGLT1 as a unique model system
  143. Role of genetic variation in the human sodium–Glucose cotransporter 2 gene (SGLT2) in Glucose homeostasis
  144. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
  145. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
  146. Biopharmacological studies of the aqueous extract of Lepidium sativum seeds in alloxan-induced diabetes in rats
  147. The sodium Glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores Glucose homeostasis in the male zucker diabetic fatty rat
  148. Renal and cardiac implications of sodium Glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
  149. Improved Glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of …
  150. SGLT2i: A novel approach to managing type 2 diabetes
  151. Renal effects of sodium–Glucose cotransporter-2 inhibitors in patients with type 2 diabetes and Renal impairment
  152. Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review
  153. Patient considerations in the management of type 2 diabetes–critical appraisal of dapagliflozin
  154. Clinical relevance of the selectivity of sodium-Glucose cotransporter-2 inhibitors.
  155. Ipragliflozin, a sodium–Glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
  156. A Review on Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus
  157. Protection of the kidney with sodium–Glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
  158. Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, reduces post-meal Glucose excursion in patients with type 2 diabetes by a non-Renal mechanism …
  159. SGLT Inhibition: a possible adjunctive treatment for type 1 diabetes
  160. Sodium-Glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus
  161. Update review of the safety of sodium-Glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
  162. Sodium-coupled Glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
  163. Preclinical Species and Human Disposition of (1S, 2S, 3S, 4R, 5S)-5-[4-Chloro-3-(4-ethoxybenzyl) phenyl]-1-hydroxymethyl-6, 8-dioxabicyclo [3.2. 1] octane-2 …
  164. Regulation of Renal brush-border Glucose transport in response to metabolic dysregulation
  165. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) Inhibition
  166. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
  167. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
  168. Sodium-Glucose cotransporter 2 inhibitors: the pleiotropic mechanisms of actions
  169. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis
  170. An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
  171. Type 2 diabetes: An updated overview
  172. SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose
  173. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
  174. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
  175. Sugar absorption
  176. Role of the kidney and SGLT-2 Inhibition in type 2 diabetes mellitus
  177. SGLT2 inhibitors: not just another Glucose-lowering agent
  178. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
  179. The use of sodium-Glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations
  180. Hypoglycemic activity of methanolic extract of Tectona grandis linn. Root in alloxan induced diabetic rats
  181. Effect of the desert plant Retama raetam on glycaemia in normal and streptozotocin-induced diabetic rats
  182. Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium Glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus
  183. Metformin supports the antidiabetic effect of a sodium Glucose cotransporter 2 inhibitor by suppressing endogenous Glucose production in diabetic mice
  184. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
  185. High urinary Glucose is associated with improved Renal prognosis in patients with diabetes mellitus
  186. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
  187. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized …
  188. SGLT2 inhibitors–a potential treatment for Alport syndrome
  189. Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage …
  190. Development of sodium-dependent Glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics
  191. Lepidium species as antidiabetic herbal medicines
  192. Pathophysiology of Type 2 Diabetes
  193. The effect of saffron (Crocus sativus L.) and its ingredients on the management of diabetes mellitus and dislipidemia
  194. Luseogliflozin: first global approval
  195. A mechanistic investigation into the acute effects of apple polyphenols on carbohydrate digestion and absorption
  196. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
  197. The potential role of sodium Glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
  198. Glucose lowering efficacy and pleiotropic effects of sodium-Glucose cotransporter 2 inhibitors
  199. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
  200. Diabetes Mellitus, Obesity and Phytotherapy
  201. Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
  202. Ethnobotanical Survey of Medicinal Plants Used by Traditional Healers to Treat Diabetes in the Taza Region of Morocco
  203. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
  204. Initial experience of SGLT2 inhibitor use in type 2 diabetes
  205. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes
  206. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the Renal …
  207. Pharmacologic management of type 2 diabetes mellitus: available therapies
  208. Hypoglycaemic effect of Triticum repens P. Beauv. in normal and diabetic rats
  209. Effects of diuretics on sodium-dependent Glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
  210. Mechanism and efficacy of new anti-diabetic medications
  211. Cardiovascular effects of sodium Glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
  212. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes …
  213. Inhibitors of sodium-Glucose linked transporter 2-A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2
  214. Antinociceptive activity of aqueous extract of Lepidium sativum L. in mice
  215. Combination therapy for type 2 diabetes: dapagliflozin plus metformin
  216. A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant …
  217. Use of canagliflozin in combination with and compared to incretin-based therapies in type 2 diabetes
  218. Comparisons of weight changes between sodium‐Glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes …
  219. Diabetes and medicinal plants-A review
  220. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats
  221. Role of insulin in the abnormal glucagon secretory response to hypoglycemia in type 1 diabetes
  222. The new direction in medical
  223. Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
  224. Novel avenues for treating diabetic nephropathy: new investigational drugs
  225. Effects of phlorizin on vascular complications in diabetes db/db mice
  226. A review: antidiabetic medicinal plants used for diabetes mellitus
  227. Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial Glucose concentrations following a high-carbohydrate meal: a randomized …
  228. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
  229. ANTI-HYPERGLYCAEMIC EFFECT OF SOME UNANI FORMULATIONS IN THE MANAGEMENT OF DIABETES MELLITUS TYPE 2
  230. Drug off-target effects predicted using structural analysis in the context of a metabolic network model
  231. Effects of Zanthoxylum zanthoxyloides leaves on blood Glucose, lipid profile and some liver enzymes in alloxan induced diabetic rats
  232. Early administration of empagliflozin preserved heart function in cardioRenal syndrome in rat
  233. The sodium Glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
  234. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
  235. Efficacy and safety of sodium‐Glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
  236. Energy loss via urine and faeces–a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight
  237. Sodium Glucose co-transporter-2 inhibitor: benefits beyond glycemic control
  238. Ketone bodies for kidney injury and disease
  239. Repurposing drugs to target the diabetes epidemic
  240. A systematic Review on Antidiabetic medicinal Plants
  241. Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight …
  242. The new direction in medical management of chronic heart failure with reduced ejection fraction
  243. Role of nutrient transporters in lifestyle-related diseases
  244. SGLT-2 inhibitors-hope or hype?-an updated review
  245. Biology of human sodium Glucose transporters
  246. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
  247. New-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
  248. The role of glucagon in the acute therapeutic effects of SGLT2 Inhibition
  249. New pharmacological approaches to diabetes management
  250. Diuretic activity of methanolic extract of Physalis minima leaves
  251. New therapeutic strategies for type 2 diabetes CME
  252. Dandelion: Phytochemistry and clinical potential
  253. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes
  254. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
  255. Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
  256. Glucose lowering treatment modalities of type 2 diabetes mellitus
  257. www. OpenCME. org/course/where-do-sglt2-inhibitors-fit-spectrum-of-treatment-of-t2dm
  258. A systematic review on effect of canagliflozin in special population
  259. Selected biologically active substances and healing properties of dandelion (Taraxacum officinale)
  260. Hypoglycaemic activity and nephro-protectective effect of Bauhinia rufescens in alloxan-induced diabetic rats
  261. Lipid Accumulation Product Combined With Urine Glucose Excretion Improves the Efficiency of Diabetes Screening in Chinese Adults
  262. The Role of Adipose Tissue in Diabetic Kidney Disease
  263. Antihyperglycemic Studies on the Leaf Extract and Active Fractions of Newbouldia laevis (Bignoniaceae)
  264. Challenges for the treatment of diabetes mellitus
  265. Plants having potential antidiabetic activity: a review
  266. Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A Case Report
  267. Treatment approach to type 2 diabetes: Past, present and future
  268. OP8-3: Adaptive changes of transposed ileum and their potential roles in the metabolic benefits of bariatric surgery
  269. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
  270. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions
  271. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
  272. The effect of dapagliflozin on clinical, metabolic and Renal parameters in type 2 diabetic patient in University of Malaya Medical Centre: A single centre experience/Ho …
  273. Antidiabetics Review on Natural Products
  274. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations
  275. Potential role of yoga in management of the ominous octet: Adding a new facet to type 2 diabetes management and prevention
  276. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote Glucose disposal and inflammation
  277. Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: A double-blinded …
  278. The metabolic model of heart failure: the role of sodium Glucose co-transporter-2 (SGLT-2) Inhibition
  279. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload
  280. Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
  281. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
  282. Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability
  283. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in …
  284. PE-4: Effects of polydextrose on glycemic and insulinemic responses in healthy normal weight and overweight women when consumed during a breakfast meal
  285. Assessing the kidney function parameters glomerular filtration rate and effective Renal plasma flow with dynamic FDG-PET/MRI in healthy subjects
  286. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
  287. The therapeutic journey of benzimidazoles: a review
  288. Sodium-Glucose cotransporter 2 inhibitors and cardiovascular outcomes
  289. Glucose transport at the Renal brush border membrane: GLUT2 and the involvement of PKC-βI
  290. Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
  291. Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
  292. Our Practice
  293. Asian Journal of Phytomedicine and Clinical Research
  294. Identification of key nodes of type 2 diabetes mellitus protein interactome and study of their interactions with phloridzin
  295. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
  296. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
  297. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study
  298. Novel therapeutic agents for the treatment of diabetic kidney disease
  299. Pharmacognosy, phytochemistry, pharmacology and clinical applications of Taraxacum officinale
  300. The Future of Diabetes Therapy
  301. Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin: Original article: Roden M, Weng J …
  302. Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects
  303. Anti-ulcerogenic effects and anti-oxidative properties of Ceiba pentandra leaves on alloxan-induced diabetic rats
  304. A new analytical method for determination of dolutegravir and rilpivirine in pharmaceutical formulations by RP-HPLC method
  305. Arterial pressure lability is improved by sodium-Glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
  306. Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin–induced diabetic albino …
  307. Our Practice Newsletter: By Pharmacists For Pharmacists, issue 3
  308. Diabetes mellitus and use of medicinal plants for its treatment
  309. Present and future challenges in Type 2 diabetes
  310. Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
  311. Antidiabetic attributes of desert and steppic plants: a review
  312. Diabetes mellitus and hypertension: a dual threat
  313. Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice
  314. Therapeutic role of fibroblast growth factor 21 (FGF21) in the amelioration of chronic diseases
  315. Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET …
  316. Drug utilization patterns in patients with diabetes initiating sodium Glucose co-transporter-2 inhibitors (SGLT2i) in Japan: a multi-database study (2014–2017)
  317. Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study
  318. Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-Glucose cotransporter SGLT1 with high affinity
  319. Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study
  320. Some selected medicinal plants with antidiabetic potentials
  321. Pharmacologic treatment options for type 1 diabetes: what’s new?
  322. Contribution to the study of medicinal plants used in the treatment of diabetes, obesity and hypertension in Tafilalet region (Morocco)
  323. The physiological effects of dandelion (Taraxacum officinale) in type 2 diabetes
  324. Diabetes and cardiovascular risk in Renal transplant patients
  325. Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
  326. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials
  327. OP8-2: The effect of bariatric surgery on fatty acid uptake and associated gene expression in abdominal subcutaneous adipose tissue of morbidly obese women
  328. Repurposing existing drugs for COVID-19: an endocrinology perspective
  329. SGLT-2 Inhibition in the kidney: changing paradigms in the treatment of type 2 diabetes mellitus
  330. Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
  331. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose …
  332. Approach to diabetes management in patients with CVD
  333. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
  334. Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
  335. The Ameliorative Potential of Saffron Against the Histological and Immunohistochemical Changes in Kidney of Albino Mice Due to Streptozotocin-Induced Diabetes …
  336. Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
  337. PE-1: Comparing the efficacy of different health education tools for improving blood Glucose control in patients with type 2 diabetes
  338. PE-2: Assessment of universal healthcare coverage of diabetes prevalence in a north India district: a rapid survey in urban and rural areas
  339. Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/Glucose‐cotransporter 2 …
  340. Hypoglycaemic and Hypolipidemic Effects of Black Brand of Lipton Tea (Camellia sinensis) on Normal Male Albino Rats
  341. Anti sense and sensibility: Renal and skin effects of (antisense) oligonucleotides
  342. β-Cell plasticity
  343. Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
  344. Benzimidazole: Journey from Single Targeting to Multitargeting Molecule
  345. Gut mechanisms linking intestinal sweet sensing to glycemic control
  346. Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
  347. Evaluation of antioxidant, hypoglycemic and hypolipidemic effects of the phytoconstituents of Cinnamomum tamala in rats
  348. OP8-4: Plasmalogens regulate macrophage polarization and protect against adipose tissue inflammation in high fat diet-fed mice
  349. PE-3: Artificial sweeteners content in sugar free products and public attitude of use in Muscat, Oman
  350. Silica-coated magnetic nanoparticles induce Glucose metabolic dysfunction in vitro via the generation of reactive oxygen species
  351. The relationship between peripheral Glucose utilisation and insulin sensitivity in the regulation of hepatic Glucose production: studies in normal and alloxan‐diabetic …
  352. Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model
  353. Nonlinear ODE mathematical analysis of the insulin-Glucose model in the presence of a condition in glycemia function H (G).
  354. A review: Medicinal plants and its impact on diabetes
  355. Antidiabetic, antioxidant and anti inflammatory properties of water and n-butanol soluble extracts from Saharian Anvillea radiata in high-fat-diet fed mice
  356. Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in Diabetes
  357. Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy
  358. Hypoglycemic and hypolipidemic effects of ethyl acetate leaf extract of Vitex simplicifolia in alloxan induced diabetic wister rats
  359. Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model Medhat M. Menshawy1 Abdel Razik H. Farrag 2, Sayed A. El …
  360. Role of Canagliflozin on function of CD34+ ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
  361. The Effect of Empagliflozin on Left Ventricular Mass and Myocardial Extracellular Volume in Patients with Type 2 Diabetes and Cardiovascular Disease
  362. Cress seed (lepidium sativum) role in the healthy processed spread cheese and its anti-diabetic activity
  363. Possible ways to improve postprandial Glucose control in type 1 diabetes
  364. New therapeutic agents for glycemic control in diabetes mellitus
  365. Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
  366. Role of some Egyptian medicinal plants against liver and kidney toxicity induced by cadmium chloride
  367. A new analytical method for determination of ledipasvir and sofosbuvir in pharmaceutical formulations by HPLC method
  368. Evaluation of medicinal plants used to diabetes treatment
  369. Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a …
  370. Skeletal muscle basal AMP-activated protein kinase activity is chronically elevated in alloxan-diabetic dogs: impact of exercise
  371. HERBAL INTERVENTIONS IN MANAGING DIABETES MELLITUS: A REVIEW
  372. Options for empagliflozin in combination therapy in type 2 diabetes mellitus
  373. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial
  374. LEELA MADHURI POLA1
  375. The effects of plant-derived oleanolic acid on kidney function in male Sprague-Dawley rats and, in cell lines of the kidney and liver.
  376. Novel research strategies of benzimidazole derivatives: a review
  377. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
  378. Type 2 diabetes mellitus and the elderly: an update on drugs used to treat glycaemia
  379. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
  380. Natural Products Derived from the Mediterranean Diet with Antidiabetic Activity: from Insulin Mimetic Hypoglycemic to Nutriepigenetic Modulator Compounds
  381. Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
  382. Prevailing hyperglycemia is critical in the regulation of Glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs
  383. Factors influencing seed germination of the pastoral plant Retama raetam subsp. bovei (Fabaceae): interactive effects of fruit morphology, salinity, and osmotic stress
  384. on Pharmacometrics 2014 (ACoP5)
  385. Polyphenols of apples and their potential health benefits
  386. Endothelial Dysfunction in Diabetes: An Update on Mechanisms and Therapeutic Targets
  387. Studies on kidney pathophysiological analyses in SDT fatty rat, a novel obese diabetic model
  388. 19 Interview| Prof. dr. U. Beuers
  389. Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study.
  390. Evaluation of the stability of exenatide in aqueous solutions
  391. Clinical Trial Number NCT02635386
  392. Medicinal plants used for the treatment of diabetes and its long-term complications
  393. Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent …
  394. Fruit and vegetable waste management: Conventional and emerging approaches
  395. Diabetes mellitus and cardiovascular disease in the elderly
  396. CONTINUOUS Glucose MONITORING 1-OR
  397. NURDIANA BINTI SAMSULRIZAL
  398. The in vitro and in vivo anti-oxidative and anti-diabetic effects of some African medicinal plants and the identification of the bioactive compounds.
  399. In-depth Studies of the Antioxidant Profile of Aegle marmelos and Its Impact on Healthy and Type II Diabetes Mellitus Subjects
  400. Mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Effective diet against o minous octet
  401. Investigation of CPR knowledge dependence on driving experience and participation in first aid training
  402. The development and health of premature infants born before the 30th pregnancy week at the age of six
  403. Evaluation of mechanical power caused by different mechanical lung ventilation methods
  404. Neurological complications of pandemic A (H1N1) 2009PDM, post-pandemic (H1N1) V, and seasonal influenza A
  405. INSULIN TREATMENT IN TYPE 2 DIABETES
  406. General anesthesia from patients perspective: what myths are most common?
  407. Roots/Health Benefits of Apples
Related Posts

Visceral Adiposity

Medicinal Mushrooms

Insulin & Cancer: How Insulin Literally Protects Cancer Cells From Being Killed

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping